Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ACHN-383 and ACHN-789 in Healthy Subjects
NCT03163550Phase 1Completed
- Sponsor
- Achaogen, Inc.
- Start
- May 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ceftibuten and clavulanic acid in complicated urinary tract infection (cUTI) and acute pyelonephritis (5 cohorts), sponsored by Achaogen, Inc. Primary endpoints: Changes from baseline in clinical laboratory values at 26 days, Changes from baseline in vital signs at 26 days and 2 more. Started May 2017; status: completed.
02
Drugs
ceftibutenclavulanic acid
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT03163550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163550.